Trial Profile
A phase I, multicenter, dose-escalation study of MDX-1100 (anti-CXCL10 human monoclonal antibody) in patients with active ulcerative colitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Eldelumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Medarex
- 25 Sep 2009 New trial record.